Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.
Esperion Therapeutics Taps The Chase Group to Fill Newly Created Role
Esperion Therapeutics has retained The Chase Group, Inc. to secure an Executive Director, Project Management. This newly created key leadership position will elevate internal collaboration for the organization as it develops and commercializes first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Seasoned executives with CVOT project management leadership are encouraged to contact Bonnie Stofer for confidential consideration at bonnie@chasegroup.com.- Categories: Life Sciences, Pharmaceutical, Research & Development
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program…
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… -
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in… -
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate…